CN113242736A - 一种治疗肺动脉高压和相关性肺动脉高压的方法 - Google Patents

一种治疗肺动脉高压和相关性肺动脉高压的方法 Download PDF

Info

Publication number
CN113242736A
CN113242736A CN201980083698.9A CN201980083698A CN113242736A CN 113242736 A CN113242736 A CN 113242736A CN 201980083698 A CN201980083698 A CN 201980083698A CN 113242736 A CN113242736 A CN 113242736A
Authority
CN
China
Prior art keywords
compound
diazaspiro
trifluoroethoxy
decane
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201980083698.9A
Other languages
English (en)
Chinese (zh)
Inventor
S·灵
M·阿隆索-加力西亚
T·帕克
J·鲁尔卡
D·卡朋特
M·罗兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altawante Science
Original Assignee
Altawante Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altawante Science filed Critical Altawante Science
Publication of CN113242736A publication Critical patent/CN113242736A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980083698.9A 2018-11-16 2019-11-15 一种治疗肺动脉高压和相关性肺动脉高压的方法 Withdrawn CN113242736A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862768575P 2018-11-16 2018-11-16
US62/768,575 2018-11-16
PCT/IB2019/001224 WO2020099926A1 (en) 2018-11-16 2019-11-15 A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
CN113242736A true CN113242736A (zh) 2021-08-10

Family

ID=69182543

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980083698.9A Withdrawn CN113242736A (zh) 2018-11-16 2019-11-15 一种治疗肺动脉高压和相关性肺动脉高压的方法

Country Status (8)

Country Link
US (2) US11413287B2 (OSRAM)
EP (1) EP3880203A1 (OSRAM)
JP (2) JP2022507533A (OSRAM)
KR (1) KR20210105343A (OSRAM)
CN (1) CN113242736A (OSRAM)
AU (1) AU2019382168A1 (OSRAM)
CA (1) CA3119909A1 (OSRAM)
WO (1) WO2020099926A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210105343A (ko) 2018-11-16 2021-08-26 알타반트 사이언시스 게엠베하 폐동맥 고혈압 및 관련 폐동맥 고혈압의 치료 방법
US20200188399A1 (en) * 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating interstitial lung disease
WO2020157577A1 (en) * 2019-01-30 2020-08-06 Altavant Sciences Gmbh A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl
JP2022525202A (ja) * 2019-03-15 2022-05-11 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と１日あたりの投薬量
WO2023062595A1 (en) 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103228648A (zh) * 2010-11-05 2013-07-31 莱西肯医药有限公司 (s)-2-氨基-3-(4-(2-氨基-6-((r)-1-(4-氯-2-(3-甲基-1h-吡唑-1-基)苯基)-2,2,2-三氟乙氧基)嘧啶-4-基)苯基)丙酸的晶体形式
CN105764902A (zh) * 2013-09-06 2016-07-13 卡罗斯制药公司 作为色氨酸羟化酶抑制剂的螺环化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100046189A (ko) 2007-07-11 2010-05-06 렉시컨 파마슈티컬스 인코퍼레이티드 폐고혈압 및 관련 질환 및 장애의 치료를 위한 방법 및 조성물
US9399741B2 (en) 2013-10-09 2016-07-26 Uop Llc Methods and apparatuses for desulfurizing hydrocarbon streams
KR20210102887A (ko) * 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
KR20210105343A (ko) 2018-11-16 2021-08-26 알타반트 사이언시스 게엠베하 폐동맥 고혈압 및 관련 폐동맥 고혈압의 치료 방법
US20200188399A1 (en) * 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating interstitial lung disease
US20200188398A1 (en) * 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating sarcoidosis-associated pulmonary hypertension
WO2020157577A1 (en) 2019-01-30 2020-08-06 Altavant Sciences Gmbh A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl
JP2022525202A (ja) 2019-03-15 2022-05-11 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と１日あたりの投薬量
CN115379825A (zh) 2020-01-31 2022-11-22 阿尔塔万特科学公司 用rodatristat治疗肺动脉高压的剂量和方法
US11937070B2 (en) 2021-07-01 2024-03-19 Tencent America LLC Layered description of space of interest
WO2023079486A1 (en) 2021-11-03 2023-05-11 Altavant Sciences Gmbh Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103228648A (zh) * 2010-11-05 2013-07-31 莱西肯医药有限公司 (s)-2-氨基-3-(4-(2-氨基-6-((r)-1-(4-氯-2-(3-甲基-1h-吡唑-1-基)苯基)-2,2,2-三氟乙氧基)嘧啶-4-基)苯基)丙酸的晶体形式
CN105764902A (zh) * 2013-09-06 2016-07-13 卡罗斯制药公司 作为色氨酸羟化酶抑制剂的螺环化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBERT J. AIELLO ET AL.: "Tryptophan hydroxylase 1(TPH1) inhibition impacts pulmonary vascular remodeling in two rat models of pulmonary hypertension", 《J PHARMACOL EXP THER》, vol. 360, no. 2, pages 1 *

Also Published As

Publication number Publication date
EP3880203A1 (en) 2021-09-22
WO2020099926A1 (en) 2020-05-22
US11413287B2 (en) 2022-08-16
CA3119909A1 (en) 2020-05-22
US20200155552A1 (en) 2020-05-21
US11911382B2 (en) 2024-02-27
AU2019382168A1 (en) 2021-06-03
JP2024019691A (ja) 2024-02-09
KR20210105343A (ko) 2021-08-26
US20230000866A1 (en) 2023-01-05
JP2022507533A (ja) 2022-01-18

Similar Documents

Publication Publication Date Title
KR20210105343A (ko) 폐동맥 고혈압 및 관련 폐동맥 고혈압의 치료 방법
US7834056B2 (en) Pharmaceutical composition for gout
CN113784717A (zh) 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药
JP5788527B2 (ja) キナーゼ阻害剤の副作用低減剤
US20220096475A1 (en) Method for treating sarcoidosis-associated pulmonary hypertension
KR100404303B1 (ko) 올티프라즈의 간섬유화 및 간경화 진행의 예방 및치료제로서의 용도 및 올티프라즈를 주성분으로 함유하는제약 조성물
CA3157656A1 (fr) Utilisation de nictotinamide mononucleotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoide et compositions correspondantes
HK40058221A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
HK40065546A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
CN108503651B (zh) 一种用于治疗脑卒中的螺环化合物
JP6976577B2 (ja) ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤
EP0310259B1 (en) Eperisone as a hypotensive agent
JP6875747B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
BE829197A (fr) Compositions anti-inflammatoires, leur preparation et leur utilisation
CN118871096A (zh) 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物
CN112516121A (zh) 包含牛磺酸和别嘌醇的组合物及其医药用途
HK40054971B (zh) 治疗脂肪性肝病和/或脂肪性肝炎的方法
WO2005000293A1 (ja) 脳血管障害に伴う過活動膀胱治療剤
JPWO2018012634A1 (ja) 不飽和複素５員環含有化合物を含有する肺高血圧症の予防又は治療剤
US20180098967A1 (en) Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40058221

Country of ref document: HK

WW01 Invention patent application withdrawn after publication

Application publication date: 20210810

WW01 Invention patent application withdrawn after publication